Lokavant is a technology company.
Lokavant has raised $21.0M across 1 funding round.
Lokavant has raised $21.0M in total across 1 funding round.
Lokavant is a clinical intelligence company founded in 2020 that builds an AI-powered platform to improve clinical trial execution by aggregating real-time data from disparate sources, providing predictive analytics, and enabling risk-based monitoring for study teams.[1][2][5] It serves pharmaceutical sponsors and contract research organizations (CROs) like Parexel, solving key problems in drug development such as operational risks, enrollment forecasting, and trial inefficiencies that delay therapies and inflate costs—powered by a proprietary dataset from over 2,000 (now expanded to 500,000) historical trials for ≥80% confident predictions and 70x better forecasting than traditional methods.[2][3][5][6] With $29M in total funding including an $8M recent round, Lokavant has grown its team, launched AI feasibility tools, and secured enterprise deals, demonstrating strong momentum in a market where trials often fail due to execution errors.[4]
Lokavant emerged in January 2020 as a spinout from Roivant Sciences, a NASDAQ-listed biopharmaceutical company, with the mission to prevent clinical trial failures from operational errors.[2][3] Rohit Nambisan, previously Head of Digital Product at Roivant, became President, leading a team that identified persistent R&D risks despite massive investments—drawing from Roivant's experience across tens of drugs in development.[2][3] Early traction came swiftly with a multi-year enterprise license to global CRO Parexel, which deployed the platform for real-time risk monitoring to accelerate therapies.[2] Headquartered in New York with around 45 employees, Lokavant has since expanded its offerings, including AI feasibility solutions and a source-agnostic data engine, fueled by subsequent funding and team growth.[1][4]
Lokavant rides the wave of AI-driven drug development, addressing a $2.6B+ clinical trials market plagued by 90% failure rates, high costs (often hundreds of millions per trial), and delays from poor data visibility and risk prediction.[2][3] Its timing aligns with post-pandemic demands for faster, decentralized trials and real-world evidence, amplified by regulatory pushes for efficiency (e.g., FDA's risk-based monitoring emphasis). Market forces like exploding data volumes from wearables/IoT and biopharma's digital transformation favor Lokavant's source-agnostic engine, reducing R&D timelines by 20-30% via proactive insights.[1][5] By partnering with AWS and CROs like Parexel, it influences the ecosystem, standardizing predictive trial intelligence and enabling smaller biotechs to compete with big pharma.[2][3]
Lokavant is poised to dominate clinical trial AI with Spectrum™ expansions into mid-study re-forecasting and broader feasibility tools, targeting deeper CRO/sponsor penetration amid rising trial complexity.[4][6] Trends like multimodal data integration, generative AI for simulations, and value-based pricing will propel growth, potentially scaling its dataset to millions of trials for near-perfect predictions. Its influence may evolve from execution optimizer to full trial orchestrator, cutting industry costs by billions—ensuring no trial fails on operations, as promised from its Roivant roots.[2]
Lokavant has raised $21.0M in total across 1 funding round.
Lokavant's investors include Edison Ventures.
Lokavant has raised $21.0M across 1 funding round. Most recently, it raised $21.0M Series A in December 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2022 | $21.0M Series A | Edison Ventures |